Cannabis
CoinShares Lists Chainlink & Uniswap ETPs on Xetra
CoinShares (“the Company”) (Nasdaq First North Growth Market: CS; US OTCQX: CNSRF), Europe’s largest digital asset investment firm with US$3.3bn* in AUM, today announced the launch of two physically-backed ETPs on Germany’s main market Xetra.
CoinShares Physical Chainlink (Ticker: CCHA) and CoinShares Physical Uniswap (Ticker: CIWP) have been built to leverage the Company’s technology platform, Galata, which connects CeFi platforms to digital asset protocols and markets and will allow investors to capture the growth and continued adoption of new form financial services replicated on cryptocurrency rails.
- Management Fee: 1.50% p.a.
- ISIN: GB00BMWB4910
- Ticker: CCHA
- WKN: A3GYRF
Chainlink is an oracle protocol designed to bridge real-world information to the smart contracts running on a blockchain platform. While often serving as a key foundational support in general crypto applications, Chainlink is a primary data provider for exchange, lending, and asset management protocols. As a result, Chainlink price feeds are a critical reference point in the integrity of DeFi markets, providing the information necessary to trigger liquidation, mint/burn operations, and settle derivative agreements.
- Management Fee: 1.50% p.a.
- ISIN: GB00BNRRG624
- Ticker: CIWP
- WKN: A3GYRG
Launched in 2018, Uniswap is a tenured exchange application that remains the leader in enabling users to transact digital assets within a cryptocurrency platform. Uniswap’s novel design enables users to both trade and provide the liquidity that supports trading activities within its application, creating a two-sided and self-sustaining marketplace whereby liquidity providers share in the revenue generated by traders’ fees. To sum up, Uniswap is a leading alternative to centralized exchanges.
Frank Spiteri, CoinShares’ Chief Revenue Officer, commented on the news, “As the digital assets sector evolves, so too does investor interest in protocols beyond Bitcoin and Ethereum. A more thematic approach to digital assets is emerging amongst those most familiar with crypto, and we expect that trend to continue as research and investor education improves. We are excited to add both Chainlink and Uniswap to our lineup of ETPs, allowing investors to access specific key areas of the digital asset ecosystem via cost-effective, listed regulated products.”
This double launch brings the total number of ETPs listed by CoinShares so far in 2022 to seven. Last week, the firm announced the launch of CoinShares FTX Physical FTX Token in partnership with leading regulated cryptocurrency exchange FTX, with seed capital of approximately US$40M.
Cannabis
North America Legal Cannabis Industry Report 2024: Market to Grow at a CAGR of 26.65% During 2023-2032, Bank Loans Boosting Business Growth
Cannabis
Global Legal Marijuana Strategic Business Report 2024: A $125+ Billion Market by 2030 Featuring Aphria, Aurora Cannabis, Beacon Medical, Canopy Growth, Cronos, OrganiGram, Tikun Olam, Tilray, Wayland
Cannabis
Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa
-
Cannabis2 weeks ago
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
-
Humboldt2 weeks ago
Humboldt Seed Company partners with Apollo Green to bring California cannabis genetics to the global marketplace
-
Cannabis2 weeks ago
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical
-
Cannabis2 weeks ago
Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III
-
Cannabis7 days ago
IM Cannabis Reports First Quarter Financial Results
-
Cannabis6 days ago
Mikra Announces Partnership with Virun NutraBiosciences Inc. and Releases CELLF 2.0
-
Innocan5 days ago
Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey
-
Cannabis2 days ago
Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa